Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors while in the central anxious system, conolidine modulates alternate molecular targets. A Science Developments study uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://franky019lzn7.theisblog.com/profile